Hikma CEO's Resignation No Surprise After Stock Loss, Profit Outlook Cut -- Market Talk

Dow Jones

2025/12/15

1313 GMT - Hikma Pharmaceuticals's announcement that Chief Executive Riad Mishlawi would step down today is no surprise after the company's shares fell around 25% this year, AJ Bell analysts write."[The London-based drugmaker] has been the master of its own downfall thanks to delays to a new U.K. manufacturing facility and issues in its supply chain," the analysts say. Mishlawi's departure follows a disappointing update last month that included a significantly damaging cut to medium-term profit forecasts, they write. Additional challenges include stiff competition in generic drugs, leaving investors to hope for the return of former boss Said Darwazah, they add. Shares are down 1.25% at 14.97 pounds. (william.gray@wsj.com)

(END) Dow Jones Newswires

December 15, 2025 08:13 ET (13:13 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2591492916"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2591492916\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2591492916?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591492916","market":"fut","top_or_hot":-1,"title":"Hikma CEO's Resignation No Surprise After Stock Loss, Profit Outlook Cut -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1313 GMT - Hikma Pharmaceuticals's announcement that Chief Executive Riad Mishlawi would step down today is no surprise after the company's shares fell around 25% this year, AJ Bell analysts write.\"[The London-based drugmaker] has been the master of its own downfall thanks to delays to a new U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. manufacturing facility and issues in its supply chain,\" the analysts say. Mishlawi's departure follows a disappointing update last month that included a significantly damaging cut to medium-term profit forecasts, they write. Additional challenges include stiff competition in generic drugs, leaving investors to hope for the return of former boss Said Darwazah, they add. Shares are down 1.25% at 14.97 pounds. (william.gray@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 15, 2025 08:13 ET (13:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hikma CEO's Resignation No Surprise After Stock Loss, Profit Outlook Cut -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHikma CEO's Resignation No Surprise After Stock Loss, Profit Outlook Cut -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-15 21:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1313 GMT - Hikma Pharmaceuticals's announcement that Chief Executive Riad Mishlawi would step down today is no surprise after the company's shares fell around 25% this year, AJ Bell analysts write.\"[The London-based drugmaker] has been the master of its own downfall thanks to delays to a new U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. manufacturing facility and issues in its supply chain,\" the analysts say. Mishlawi's departure follows a disappointing update last month that included a significantly damaging cut to medium-term profit forecasts, they write. Additional challenges include stiff competition in generic drugs, leaving investors to hope for the return of former boss Said Darwazah, they add. Shares are down 1.25% at 14.97 pounds. (william.gray@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 15, 2025 08:13 ET (13:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HKMPY","symbol_name":"Hikma Pharmaceuticals plc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2591492916","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591492916","pubTimestamp":1765804380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1313 GMT - Hikma Pharmaceuticals's announcement that Chief Executive Riad Mishlawi would step down today is no surprise after the company's shares fell around 25% this year, AJ Bell analysts write.\"[The London-based drugmaker] has been the master of its own downfall thanks to delays to a new U.K. manufacturing facility and issues in its supply chain,\" the analysts say. Mishlawi's departure follows a disappointing update last month that included a significantly damaging cut to medium-term profit forecasts, they write. Additional challenges include stiff competition in generic drugs, leaving investors to hope for the return of former boss Said Darwazah, they add. Shares are down 1.25% at 14.97 pounds. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HKMPY":"Hikma Pharmaceuticals plc.","BK4007":"制药"},"translate_title":"Hikma首席执行官在股价下跌、利润前景下调后辞职并不令人意外——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKMPY":0.9},"content_text":"1313 GMT - Hikma Pharmaceuticals's announcement that Chief Executive Riad Mishlawi would step down today is no surprise after the company's shares fell around 25% this year, AJ Bell analysts write.\"[The London-based drugmaker] has been the master of its own downfall thanks to delays to a new U.K. manufacturing facility and issues in its supply chain,\" the analysts say. Mishlawi's departure follows a disappointing update last month that included a significantly damaging cut to medium-term profit forecasts, they write. Additional challenges include stiff competition in generic drugs, leaving investors to hope for the return of former boss Said Darwazah, they add. Shares are down 1.25% at 14.97 pounds. (william.gray@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 08:13 ET (13:13 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}